An interventional study of Personalized tactile cueing and Fixed tactile cueing in Parkinson Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Parkinson Disease by Oregon Health and Science University — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Oregon Health and Science University.
Among the 36 studies in Parkinson Disease by Oregon Health and Science University, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 34th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 36 studies in Parkinson Disease by Oregon Health and Science University are open now, in 2 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States, Brazil
Ages 50–80
Oregon Health and Science University · Sites in United States
Ages 40–90
Oregon Health and Science University · Sites in United States
Ages 55–85
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 45 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 22 across the 28 interventional studies, 17 across the 8 observational. Of the 26 that completed or were terminated, 10 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
3 of the studies in Parkinson Disease by Oregon Health and Science University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06815302Oregon Health and Science UniversityTURN-IT FOG: Improving Turning and Freezing of Gait in People With PD | 2026-12-31 |
| NCT05680597Oregon Health and Science UniversityBalance Tele-Rehab in Parkinson's Disease | 2027-06 |
| NCT05818189Oregon Health and Science UniversityCortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Parkinson Disease by Oregon Health and Science University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). The researchers predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. In addition, the researchers will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.
This project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with Parkinson's Disease, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in Parkinson's Disease.
Cortical correlates of gait automaticity in Parkinson's disease: impact of cueing
A well-recognized hallmark of healthy walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding, executive resources. It has been proposed that many walking abnormalities in people with Parkinson's disease (PD) are characterized by a shift in locomotor control from healthy automaticity to compensatory, executive control. This shift to less automaticity is potentially detrimental to walking performance as executive control strategies are not optimized for locomotor control, place excessive demands on a limited cognitive reserve, and continuously require attention. It has been hypothesized that as gait becomes more variable, as in people with Parkinson's Disease, control of gait is less automatic, i.e., requires more prefrontal cortex involvement. However, as gait variability is not a direct measure of automaticity, it is controversial whether it truly reflects impaired gait automaticity or impaired gait stability (i.e., dynamic balance). The recent development of wireless, functional, near-infrared spectroscopy (fNIRS) of the brain provides more direct, physiological measures of automaticity, such as reduced prefrontal cortex activity. However, the contribution of other cortical areas to the concept of gait automaticity is largely unknown. Here, for the first time, the researchers will use a full cap fNIRS system to monitor cortical activity in multiple brain areas and wearable, inertial sensors to determine how cognitive abilities, levodopa, and cueing influence gait automaticity.
The effects of cognitive dysfunction and interventions on gait in people with Parkinson's Disease are complex. Impaired executive function has been associated with impaired gait and balance in PD, but it is not known if this relationship is due to the inability to compensate for poor basal ganglia control of gait automaticity with increased prefrontal cortex activity while walking. Sensory cueing may increase gait speed and reduce prefrontal activity but unlike levodopa, it may result in reduced gait variability due to enhanced automaticity. The researchers recently developed a novel type of personalized (triggered by the subject's own walking pattern), step-synchronized tactile stimulation on the wrists to improve the quality of gait and turning in people with Parkinson's Disease. The researchers will now compare the effects of cognitive dysfunction, dopaminergic medication, and tactile cueing on the quality of gait and turning and investigate whether improvements reflect changes in prefrontal activity.
This project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with PD, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in Parkinson's Disease.
The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). We predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. A secondary analysis will explore whether the effect of cueing on gait automaticity is influenced by cognitive dysfunction. In addition, we will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial. We will explore feasibility and efficacy of cueing in daily life comparing data of gait and turning from a week of continuous monitoring without and with using the tactile cueing. In addition, we will test whether any retention on gait and turning is present by adding a third week of continuous monitoring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Personalized, step-synchronized tactile cueing, enhancing proprioceptive inputs, in the form of real-time, closed-loop tactile feedback signaling left and right stance times while walking
Device: Personalized tactile cueing
Tactile cueing at fixed intervals, enhancing proprioceptive inputs, in the form of open-loop tactile feedback (fixed rhythm) signaling left and right stance times while walking
Device: Fixed tactile cueing
We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
Also known as: personalized
We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
Also known as: fixed
Prefrontal cortex activity
Oxygenated hemoglobin over the prefrontal cortex measures by fNIRS
Time frame: day 1
Parietal cortex activity
Oxygenated hemoglobin over the parietal cortex measures by fNIRS
Time frame: day 1
Stride time variability
Variability of stride time during 2 minute walking
Time frame: day 1
Local Dynamic Stability
Stability during gait is assessed by phase dependent local dynamic stability (LDS) measures of the trunk acceleration while walking
Time frame: day 1
Turn duration
Average duration of 360 turning while performing a 1 minute turning in place task
Time frame: day 1
Turn jerk
Average turning smoothness while performing a 1 minute turning in place task
Time frame: day 1
Supplementary motor area cortical activity
Oxygenated hemoglobin over the SMA cortex measures by fNIRS
Time frame: day 1
Occipital cortical activity
Oxygenated hemoglobin over the visual cortex measures by fNIRS
Time frame: day 1
Gait speed
Average gait speed during 2 minute walking
Time frame: day 1
Gait speed variability
Variability of gait speed during 2 minute walking
Time frame: day 1
Stride time
Average stride duration during 2 minute walking
Time frame: day 1
Stride length
Average stride length during 2 minute walking
Time frame: day 1
Stride length variability
Variability of stride length during 2 minute walking
Time frame: day 1
Turn duration variability
Variability of turning duration while performing a 1 minute turning in place task
Time frame: day 1
Turn jerk variability
Variability of turning smoothness while performing a 1 minute turning in place task
Time frame: day 1
Number of steps during turning
Average number of steps while performing a 1 minute turning in place task
Time frame: day 1
Number of steps during turning variability
Variability of number of steps while performing a 1 minute turning in place task
Time frame: day 1
Turn velocity
Average turning velocity while performing a 1 minute turning in place task
Time frame: day 1
Turn velocity variability
Variability of turning velocity while performing a 1 minute turning in place task
Time frame: day 1
Plan to share: Yes — Upon reasonable request, we can share de-identified data related to study outcomes measures.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data would be available 6 months after the end of data collection. Data will be stored in our laboratory data repository and so will be available indefinitely.
Access criteria: Data will not be stored on a public website, however researchers may contact us for access to the data. We will send data electronically via a secure server.
Started Jan 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 32 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →